Jefferies analyst Dennis Ding reiterated a Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report) yesterday and set a price target of $24.00. The company’s shares closed yesterday at $10.71.
According to TipRanks, Ding is a 3-star analyst with an average return of 5.5% and a 46.67% success rate. Ding covers the Healthcare sector, focusing on stocks such as Cara Therapeutics, Roivant Sciences, and Esperion.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NewAmsterdam Pharma Company with a $22.50 average price target.
See today’s best-performing stocks on TipRanks >>
NAMS market cap is currently $877.3M and has a P/E ratio of -52.24.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Frazier Lifesciences Acquisition Corp is a blank check company.
Read More on NAMS:
- NewAmsterdam expects cash to fund operations through 2026
- NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
- NewAmsterdam reports H1 of 2023 EPS (EUR 92) vs EUR 1.35 last year
- NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease
- NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares
